8-K Announcements
6Material company update
Jun 10, 2026·SEC
Material company update
Jun 9, 2026·SEC
Material company update
Jun 5, 2026·SEC
Aditxt, Inc.(ADTX)Earnings, Financials & Key Ratios
ADTX•NASDAQ
$0.00
Price updated Jul 7, 2026
AboutAditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.Show more
- Revenue$3K-97.6%
- EBITDA-$19M+29.2%
- Net Income-$42M-21.1%
- EPS (Diluted)-1153.83+62.3%
- Gross Margin8.39%+102.3%
- EBITDA Margin-604010.02%-2870.2%
- Operating Margin-612542.22%-2845.4%
- Net Margin-1305608.79%-4978.4%
- ROE-681.6%-140.7%
ADTX Price & Volume
Aditxt, Inc. (ADTX) stock price & volume — 10-year historical chart
Loading chart...
Aditxt Faces Severe Liquidity and Solvency Crisis
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent insolvency and dilution
Key Thesis Takeaways
- Aditxt exhibits a fundamental collapse in its commercial diagnostic model, evidenced by quarterly revenue plummeting to a negligible $12,200.
- The company's reliance on massive stock-based compensation, which reached $472.8 million in 2025Q4, masks a severe underlying cash burn that threatens long-term viability.
- Investors should remain cautious as the firm's negative equity position of -$33.3 million and critical current ratio of 0.06 suggest an imminent requirement for highly dilutive financing to sustain operations.
Verdict Logic
the company's inability to generate sustainable revenue, combined with a critical current ratio of 0.06, indicates an imminent risk of insolvency and severe shareholder dilution.
ADTX Growth Metrics
Aditxt, Inc. (ADTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-84.93%
TTM-74.09%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-104.32%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1269.9%
Return on Capital
10 Years-248.64%
5 Years-259.02%
3 Years-235.23%
Last Year-300.31%
Peers Comparison
Key metrics vs top competitors for Aditxt, Inc. (ADTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.00 | $117 | — | -97.62% | -1305608.79% | -681.6% | — | |
| $0.45 | $65.98M | -1.54 | 31.28% | -998.18% | -84.55% | — | |
| $5.29 | $10.32M | -0.46 | -13.43% | -299.66% | — | — | |
| $3.50 | $145.75M | -1029.41 | 10.37% | 52.16% | — | — | |
| $74.90 | $1.46B | -7.70 | -43.89% | -284.18% | -87% | — | |
| $1.88 | $8.51M | -0.54 | 498.95% | -76996.25% | -160.55% | — |
Compare ADTX vs Peers
Aditxt, Inc. (ADTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ADTX SEC Filings & Documents
Aditxt, Inc. (ADTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ADTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ADTX Frequently Asked Questions
Aditxt, Inc. (ADTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Aditxt, Inc.'s revenue?
Aditxt, Inc. (ADTX) reported $0.0M in revenue for fiscal year 2025.
How fast is Aditxt, Inc. growing?
Aditxt, Inc. (ADTX) saw revenue decline by 97.6% over the past year.
Is ADTX profitable?
Aditxt, Inc. (ADTX) reported a net loss of $52.0M for fiscal year 2025.
Dividend & Returns
What is ADTX's return on equity?
Aditxt, Inc. (ADTX) has a return on equity (ROE) of -681.6%. Negative ROE indicates the company is unprofitable.
What is Aditxt, Inc.'s free cash flow?
Aditxt, Inc. (ADTX) had negative free cash flow of $18.6M in fiscal year 2025, likely due to heavy capital investments.